Companies: 10,795·Total market cap: $144.5T
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZNASDAQHealthcare● Active
$6.72
$-0.29(-4.14%)
Market Cap$210701528
P/E Ratio
52W High$50.4
52W Low$6.61
Overview

LENZ Therapeutics, Inc. (LENZ) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

lenz · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) measures how much investors pay for each dollar of the company's trailing earnings. LENZ's current PE ratio of N/A is calculated by dividing its stock price of $6.72 by its TTM earnings per share of -$3.48.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.47
Based on 6 analysts
EPS (TTM)
-$3.48
TTM · diluted EPS
PEG Ratio
0.03
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LENZ Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc.You
LENZ
$211MN/A-$3.48
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
ABUS
$838MN/A-$0.17
Geron Corporation
Geron Corporation
GERN
$725MN/A-$0.13
GH Research PLC
GH Research PLC
GHRS
$1.4BN/A-$0.79
Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc.
MRVI
$1.4BN/A-$0.90
Nanobiotix S.A.
Nanobiotix S.A.
NBTX
$1.8BN/A-$0.50
Prime Medicine, Inc.
Prime Medicine, Inc.
PRME
$535MN/A-$1.35

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-2.85
2024-12-31
FY2024
$-2.34
2023-12-31
FY2023
$-8.59
2022-12-31
FY2022
$-1.38
2021-12-31
FY2021
$-8.54
2020-12-31
FY2020
$-8.24
2019-12-31
FY2019
$-0.01

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) measures how much investors pay for each dollar of the company's trailing earnings. LENZ's current PE ratio of N/A is calculated by dividing its stock price of $6.72 by its TTM earnings per share of -$3.48.

PE Ratio = Stock Price ÷ EPS (TTM)
= $6.72 ÷ -$3.48 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

LENZ pe ratio · 6 questions

LENZ's current PE ratio is N/A as of 2026-06-08, based on a stock price of $6.72 and TTM EPS of -$3.48. Data sourced from Financial Modeling Prep via LENZ's SEC 10-K and 10-Q filings.

LENZ PE ratioWhat is LENZ PE ratioCurrent PE ratio of LENZLENZ PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LENZ Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08